Drugs / iPSC-EVs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07065409 | May 2025 → May 2026 overdue | Moyamoya disease | Huaqiu Zhang | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iPSC-EVs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07065409 ↗ |
| Known as | NouvSoma002-01 | “iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.” NCT07065409 ↗ |
| Route | Other | “iPSC-EVs local skin transplantation” NCT07065409 ↗ |